Through the same proprietary manufacturing process that produces HSC660, a unique human extracellular matrix (ECM) is also created and holds significant potential as a biological matrix to stimulate the regeneration of new tissue for therapeutic applications including orthopedics, soft tissue augmentation and wound healing.
Histogen’s research has shown that both its CCM and ECM products have great potential in the sports medicine, spinal disc repair, orthopedic, and dental areas. Studies conducted by outside experts have demonstrated that both products are anti-inflammatory, angiogenic, and can stimulate the growth of stem cells in damaged areas to induce tissue regeneration. The most extensive in vivo work in animals has focused on the regeneration of new hyaline cartilage and bone in full thickness knee injuries. This future product, based on Histogen’s proprietary ECM, has enormous future market potential to address the loss of cartilage in knees and other joints associated with age, osteoarthritis, rheumatoid arthritis, and injury from sports or accidents.
Soft Tissue Augmentation
Studies to date have shown that Histogen’s ECM acts as a biological scaffold to attract the patient’s own stem cells and fibroblasts to migrate into it, divide and differentiate, and generate new soft tissue. Unlike temporary fillers, this approach generates new healthy tissue similar to the patient’s own, and offers the possibility of a more permanent solution in treating deep wrinkles or acne scars, regenerating tissue after a lumpectomy, or augmenting breast tissue.
Histogen has been awarded grants from the National Science Foundation (NSF) to develop its ECM material, in combination with an antimicrobial peptide technology, for the treatment of chronic wounds. The Company has developed a wafer comprised of its ECM coated with the antimicrobial peptide which can be placed in a wound bed to simultaneously aid in tissue regeneration, prevent infection and reduce inflammation. The initial focus of the work under these grants is in the treatment of chronic wounds, specifically diabetic, venous and pressure ulcers.
For more information, please visit our Business Development page.